

**Technical Evaluation Report of Drugs/Medicines (Sole Agents of Foreign Principle) 2018-19**  
**Directorate General Health Services Punjab**

Sr.	T.E No.	Item Name	Firm Name	Advertised Specifications	Quoted Brand	Compulsory Parameters Note: Failure to comply with any compulsory parameter will result in "nonresponsiveness of the bidder for quoted item"											Marking Criteria Note: Qualifying marks are 60% i.e 36/60						Obtained Marks in Marking Criteria	Result	Remarks
						1	2	3	4	5	6	7	8	9	10	11	1	2	3	4	5	6			
						Prequalified wih DGHS	2 % bid security of estimated cost of the quoted item	Valid Drug Manufacturing License issued by DRAP (manufacturers) and valid Drug Sale License (in case of importers)	Valid Drug Registration Certificate of the quoted product	Valid GMP Certificate from Country of Manufacturer / Country of Origin	Valid Sole Agency Certificate / Authorization Certificate for the quoted item	Valid Free Sale Certificate indicating that the quoted brand is freely available in the country of manufacturer for at least two years	Compliance of quoted specifications with Advertised specifications	Undertaking Regarding "Non-Declaration of any Spurious / Adulterated Batch" by DTLs of the Punjab / any Competent Lab of quoted item	Firm undertakes that currently it is not Blacklisted / Debarred by any procuring agency	Submission of Two packs of sample for evaluation by the technical committee	Experience of Quoted Product since July 2017 to June 2018 (15) Supply of the quoted product Equivalent or Higher than the advertised quantity in Private Sector. [15] Supply of the quoted product Equivalent or higher than the advertised quantity in Public & private Sector Only [10] Supply of the quoted product at least 60% of advertised quantity in Private/Public Sector Only [5]	Bidder & Manufacturer Relationship regarding Import Experience (10) 0 to 2 years [5] Above 2 to 5 years [7] Above 5 years [10]	Local Market Business (15) 1 to 2 year [5] Above 2 to 5 years [10] Above 5 years [15]	Compliance of Quality Standards of Quoted item (5) Quality Compliance Standards (EMA/CE/JMHLW/US FDA/prequalified by WHO/The product having registration in Stringent Regulatory Authorities (SRA) Founding Regulatory Members countries as (Europe, USA, and Japan) and Standing Regulatory Members as (Canada, Switzerland & Australia), Regulatory Members (Brazil, China, Singapore, Republic of Korea).	Quality of Product (10) If samples of quoted product declared by DTL /NIH are less than 1% during last Financial Year. [10] If samples of quoted product declared by DTL /NIH are 1-2% during last Financial Year [5] If samples of quoted product declared by DTL /NIH are 2-3% during last Financial Year. [3]	Availability of Quoted Product Last Two Years (5) Developed Countries (USA/Europe/Japan) [5] Or Other Countries 1 mark per country, 05 and above countries [5]			
1	27	Inj. Insulin 70/30 W/V (Human)(30% soluble insulin & 70% Isophane insulin) 100 IU/ml	Novo Nordisk Pharma (Pvt) Ltd Karachi Pakistan	Inj. Insulin 70/30 W/V (Human) (30% soluble insulin & 70% Isophane insulin) 100 IU/ml, glass vial of 10 ml. Packed in carton with leaflet. The firm will produce batch wise cold chain data from the source or origin and thermolog data from factory to warehouse. Attach Bioequivalence/Bio similarity studies data. Product must be CE/EMA/US-FDA/WHO approved.	Brand: Mixtard Dosage Form: Suspension for Injection Potency: (30% soluble insulin & 70% Isophane insulin) 100 IU/ml Pack Size: 1x10ml vial with leaflet DRN: 010348 Mfg. By: Novo Nordisk Production SAS, 45 Avenue d'Orleans F-28000 Chartres, France MRP: 540	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	15	10	15	5	10	0	55	Non-Responsive	Undertaking not notarized

Note: Last date for the submission of grievance application is 02/02/2019, if any.